---
title: "CI Blend Pen"
slug: "ci-blend-pen"
type: "compound"
category: "Body Composition"
url: "https://peptidesciencethailand.com/compounds/ci-blend-pen"
description: "CJC-1295 and Ipamorelin combined in a ready-to-use pen for streamlined GH optimization. Blend mechanism, dosing schedule, and format advantages."
---
# CI Blend Pen

*Synergistic Growth Hormone Optimization, CJC-1295 + Ipamorelin in a Precision Auto-Injector*

**Category:** Body Composition  
**Format:** Auto-Injector Pen  
**Amount:** 10mg  
**Purity:** >99% (HPLC)

## Overview

The CI Blend Pen combines CJC-1295 (a growth hormone-releasing hormone analogue) and Ipamorelin (a selective growth hormone secretagogue) in a 10mg auto-injector pen format. This dual-peptide formulation targets growth hormone optimization through two complementary receptor systems on pituitary somatotroph cells, producing synergistic GH output significantly exceeding what either compound achieves independently. The pre-formulated pen delivery system provides precise dosing consistency and eliminates the multi-step reconstitution process required when using these peptides separately.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) composed of the first 29 amino acids of native GHRH with strategic modifications that dramatically extend its biological half-life. The native GHRH molecule has a half-life of approximately 7 minutes due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). CJC-1295 incorporates amino acid substitutions at positions 2, 8, 15, and 27 that confer resistance to DPP-IV cleavage, extending the active half-life significantly. When further modified with a Drug Affinity Complex (DAC), the peptide binds to serum albumin in the bloodstream, achieving an effective half-life of 6-8 days.

At the molecular level, CJC-1295 binds to GHRH receptors (GHRH-R) on somatotroph cells in the anterior pituitary gland. GHRH-R is a G protein-coupled receptor that, upon activation, stimulates adenylyl cyclase to produce cyclic AMP (cAMP). Elevated intracellular cAMP activates protein kinase A (PKA), which phosphorylates multiple downstream targets including CREB (cAMP response element-binding protein). CREB activation drives transcription of the GH gene, increasing both the production and secretion of growth hormone from pituitary stores. Importantly, CJC-1295 amplifies existing GH pulses but cannot initiate them independently, as GHRH signaling requires concurrent permissive signals from other pathways.

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that operates through an entirely separate receptor system. It functions as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin. GHS-R1a activation on somatotroph cells triggers a distinct intracellular cascade involving phospholipase C (PLC), inositol trisphosphate (IP3), and intracellular calcium release. The calcium signal directly triggers exocytosis of GH-containing secretory granules, initiating GH pulse release.

What distinguishes Ipamorelin from other GHS-R1a agonists is its remarkable selectivity. Research published in the European Journal of Endocrinology demonstrated that Ipamorelin produces dose-dependent growth hormone elevation without corresponding increases in adrenocorticotropic hormone (ACTH), cortisol, prolactin, or aldosterone. This selectivity profile is unique among growth hormone secretagogues. GHRP-6 and GHRP-2, earlier generation secretagogues, significantly elevate cortisol and prolactin at GH-releasing doses, producing unwanted effects including increased appetite (via cortisol), water retention (via aldosterone), and potential hormonal disruption. Ipamorelin's clean selectivity eliminates these concerns while maintaining potent GH-releasing activity.

The synergistic rationale for combining CJC-1295 and Ipamorelin is grounded in the dual-receptor model of GH regulation. Growth hormone secretion from pituitary somatotrophs is controlled by two primary inputs: stimulatory GHRH signaling (targeted by CJC-1295) and permissive ghrelin/GHS signaling (targeted by Ipamorelin). Neither pathway alone produces maximal GH output. GHRH signaling amplifies pulse amplitude but requires a concurrent permissive signal to initiate release. GHS signaling can initiate pulses but produces modest amplitude without GHRH co-stimulation. When both receptors are activated simultaneously, the resulting GH pulse is multiplicative rather than merely additive.

Clinical research examining CJC-1295 has documented significant effects on GH and IGF-1 levels. A study published in the Journal of Clinical Endocrinology and Metabolism demonstrated that a single dose of CJC-1295 produced 2-10 fold increases in mean GH concentration and 1.5-3 fold increases in IGF-1 levels sustained over 6-8 days. When combined with Ipamorelin's pulse-initiating capacity, the clinical significance of this sustained amplification is magnified, as each natural and Ipamorelin-initiated pulse occurs against a background of enhanced GHRH receptor activation.

The downstream physiological effects of optimized GH pulsatility are mediated primarily through hepatic production of Insulin-like Growth Factor 1 (IGF-1). Circulating GH stimulates IGF-1 synthesis in the liver, and IGF-1 serves as the primary effector molecule for many of growth hormone's anabolic and regenerative effects. IGF-1 promotes protein synthesis through activation of the mTOR signaling pathway, supports lipolysis through hormone-sensitive lipase activation, stimulates collagen production in connective tissue, enhances bone mineral metabolism, and modulates immune cell function.

Growth hormone itself also exerts direct effects independent of IGF-1. GH directly promotes lipolysis in adipose tissue through JAK2-STAT5 signaling, contributing to fat mobilization and utilization. It also plays roles in sleep architecture, with GH secretion naturally peaking during slow-wave sleep stages. Enhanced GH pulsatility through the CI Blend may support improved sleep quality and the restorative processes that occur during deep sleep phases.

The auto-injector pen format addresses a key practical challenge of the CJC-1295/Ipamorelin protocol. Traditional administration requires reconstitution of two separate lyophilized peptides, calculation of individual doses, and either combined or sequential injection. The CI Blend Pen delivers both peptides in a single pre-formulated dose, maintaining precise ratios and eliminating the potential for mixing errors, contamination, or inconsistent dosing that can occur with manual preparation.

The 10mg total peptide content provides a concentrated multi-dose cartridge designed for the typical protocol duration. The sealed pen system protects the peptide solution from degradation factors including UV light exposure, temperature cycling, and microbial contamination, supporting consistent potency across the usage period.

## Mechanism of Action

### Step 1: Ipamorelin GHS-R1a Receptor Activation

Ipamorelin selectively binds the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotroph cells, triggering PLC/IP3/calcium signaling to initiate growth hormone pulse release without elevating cortisol, prolactin, or aldosterone.

### Step 2: CJC-1295 GHRH Receptor Amplification

CJC-1295 binds GHRH receptors on the same somatotroph cells, activating the cAMP/PKA/CREB signaling cascade. This amplifies the magnitude of the GH pulse initiated by Ipamorelin, producing multiplicative rather than merely additive output.

### Step 3: Synergistic GH Pulse Generation

Dual-receptor activation produces GH pulses significantly larger than either peptide alone while preserving natural pulsatile release patterns and hypothalamic-pituitary feedback regulation.

### Step 4: Hepatic IGF-1 Synthesis

Elevated circulating growth hormone stimulates the liver to produce Insulin-like Growth Factor 1 (IGF-1), the primary downstream effector of GH's anabolic, regenerative, and metabolic effects via mTOR pathway activation.

### Step 5: Multi-System Physiological Response

GH and IGF-1 together promote protein synthesis, lipolysis, collagen production, bone mineral metabolism, immune function, and improved sleep architecture across multiple organ systems.

## Researched Benefits

### Synergistic Growth Hormone Optimization

The dual-receptor activation model produces GH output that significantly exceeds what either CJC-1295 or Ipamorelin achieves independently. By simultaneously stimulating both the GHRH and GHS receptor systems on pituitary somatotroph cells, the blend creates multiplicative pulse amplification while maintaining natural pulsatile release patterns.

### Clean Selectivity Profile

Ipamorelin's selectivity for GH release without elevating cortisol, prolactin, or aldosterone distinguishes this blend from other GH-optimizing protocols. The CI Blend provides growth hormone enhancement without the appetite stimulation, water retention, and stress hormone effects associated with less selective secretagogues.

### Body Composition & Recovery Support

Optimized GH pulsatility and downstream IGF-1 production support enhanced protein synthesis through mTOR activation, lipolysis through hormone-sensitive lipase engagement, and collagen production for connective tissue integrity. These combined effects may support improvements in lean tissue to adipose tissue ratio.

### Precision Pen Delivery

The auto-injector pen delivers pre-formulated CJC-1295 and Ipamorelin in a single measured dose, eliminating the need for separate reconstitution, individual dose calculations, and multiple injections. Consistent component ratios are maintained across every dose.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | One pen click administered subcutaneously, typically twice daily (morning and evening), as directed by a your specialist |
| Route | Subcutaneous injection via auto-injector pen |
| Duration | 8-12 weeks per cycle, as determined by a your specialist |
| Cycle Notes | Protocols typically include rest periods between cycles to prevent pituitary desensitization. Evening doses are often timed 30-60 minutes before sleep to align with natural nocturnal GH release patterns. Cycle duration and rest intervals should be determined by a your specialist. |
| Reconstitution | No reconstitution required. The CI Blend Pen is a pre-filled auto-injector containing 10mg of the CJC-1295 and Ipamorelin blend. Store refrigerated at 2-8 degrees Celsius. Protect from light. |

> **Specialist note:** Growth hormone optimization protocols require baseline blood work including IGF-1, fasting glucose, HbA1c, and thyroid panel. A specialist will assess whether GH-modulating compounds are appropriate based on metabolic profile, health history, and concurrent medications, and will adjust dosing throughout the protocol based on lab monitoring.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Pre-filled Auto-Injector Pen |
| Amount | 10mg total blend (CJC-1295 + Ipamorelin) |
| Purity | >99% (each component) |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Sequence | CJC-1295: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg \| Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Molecular Weight | CJC-1295: 3647.28 g/mol \| Ipamorelin: 711.85 g/mol |
| Storage | Store at 2-8 degrees Celsius. Protect from light. Do not freeze. |
| Appearance | Clear solution in auto-injector pen |

## Medical Guidance

The CI Blend directly modulates the growth hormone axis through dual receptor systems, interacting with glucose metabolism, insulin sensitivity, and thyroid function. Pre-existing conditions affecting these systems, including diabetes, thyroid disorders, insulin resistance, or history of certain proliferative conditions, require thorough specialist evaluation before initiating this protocol. Baseline and ongoing blood work monitoring IGF-1, fasting glucose, HbA1c, and thyroid markers is essential.

## Frequently Asked Questions

### What is the CI Blend and how does it work?

The CI Blend combines CJC-1295 (a GHRH analogue) and Ipamorelin (a selective GH secretagogue) in a 10mg auto-injector pen. These two peptides target different receptor systems on pituitary growth hormone-producing cells. Ipamorelin activates the GHS-R1a receptor to initiate GH pulses, while CJC-1295 activates the GHRH receptor to amplify those pulses. Together they produce synergistic GH output exceeding either compound alone.

### What medical guidance applies to the CI Blend Pen?

The CI Blend Pen is a research-quality dual-peptide formulation that modulates the growth hormone axis, which interacts with glucose metabolism, thyroid function, and insulin sensitivity. Baseline blood work and ongoing monitoring by a your specialist are essential for safe use. A specialist consultation ensures the protocol is appropriate for individual metabolic profile and health history.

### How is the CI Blend different from using CJC-1295 and Ipamorelin separately?

The CI Blend Pen delivers both peptides in a pre-formulated, single-injection format that eliminates separate reconstitution, individual dose calculations, and multiple injections. The pen maintains precise ratios between CJC-1295 and Ipamorelin across every dose, ensuring consistent dual-receptor activation and reducing preparation complexity.

### What blood work is required before starting the CI Blend?

A your specialist will typically order baseline IGF-1 levels, fasting glucose, HbA1c, complete thyroid panel (TSH, Free T3, Free T4), and a comprehensive metabolic panel before initiating the protocol. Follow-up blood work at regular intervals monitors response and ensures metabolic markers remain within appropriate ranges throughout the cycle.

### Why is Ipamorelin preferred over other growth hormone secretagogues?

Ipamorelin demonstrates a uniquely selective GH-releasing profile. Research published in the European Journal of Endocrinology confirmed that Ipamorelin produces dose-dependent growth hormone elevation without corresponding increases in cortisol, prolactin, or aldosterone. Earlier generation secretagogues like GHRP-6 elevate these hormones at GH-releasing doses, causing appetite stimulation, water retention, and potential hormonal disruption.

## Related Compounds

- /compounds/cjc-1295-ipamorelin
- /compounds/ipamorelin
- /compounds/tci-blend-pen

## Comparisons

- /compare/cjc-1295-ipamorelin-vs-tesamorelin